ASCO 2015 : l’immunothérapie sur tous les fronts de la cancérologie
En quelques années, l’immunothérapie est devenue la vedette des congrès de cancérologie. Initialement destinée au traitement du mélanome, cette nouvelle approche s’impose aujourd’hui comme une option thérapeutique efficace dans de nombreuses tumeurs solides.
Fondé sous l’impulsion de Pr Gustave Roussy, père des concepts de "discipline transversale" et de "prise en charge multidisciplinaire", l’Institut développe depuis plusieurs décennies une approche de la cancérologie fidèle aux valeurs de son fondateur : innovation, énergie, partage et bienveillance. La politique des ressources humaines constitue le ciment de telles valeurs, en permettant la création de liens essentiels entre les individus, les services, les partenaires, les patients et les soignants.
Presentations which confirm the leadership of Gustave Roussy in the field of targeted therapies and immunotherapy
Gustave Roussy’s medical researchers will unveil their research work through 56 presentations at the congress of the American Society of Clinical Oncology (ASCO). The scientific committee of ASCO has selected 22 oral communications including 5 directly submitted by the Institute, 7 posters/discussions including 5 submitted by Gustave Roussy and 25 posters.
Gustave Roussy treats patients with meningiomas, gliomas, ependymomas, medulloblastomas, cerebral lymphomas, “solitary” cerebral metastases, chordomas and other skull base tumours. A cerebral tumour is one which arises within the cranium. There are numerous types of such tumours. Their consequences and seriousness vary greatly depending on:
In addition to specific cancer treatments, care referred to as supportive is advocated to ensure that Gustave Roussy patients receive an overall management and the best possible quality of life possible.
The quality of life of patients can be changed not only by their illness, but also by secondary effects and as a result of treatment sequellae. This is why at Gustave Roussy, supportive care is an integral part of management from the onset of treatment and sometimes long after it has ended. It focuses particularly on: